Mode
Text Size
Log in / Sign up

Retrospective Study Shows 3D ResNeXt Classifier Distinguishes NTM-LD from PTB in 409 PatientsNew AI Tool Helps Doctors Tell Two Lung Infections Apart

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider external validation warranted before applying this classifier to differentiate NTM-LD from pulmonary tuberculosis.

This retrospective cohort study assessed the diagnostic performance of a 3D ResNeXt-based deep learning classifier applied to chest CT imaging. The population consisted of 409 patients with microbiologically confirmed diagnoses of Non-tuberculous mycobacterial lung disease or Pulmonary tuberculosis. Follow-up duration was not reported. Study setting was not reported. Publication type was abstract.

The primary outcome was differentiation of NTM-LD from PTB. In the training set of 329 patients, the model achieved an AUC of 0.89 and accuracy of 0.89. In the test set of 80 patients, the AUC was 0.83 and accuracy was 0.84. The classifier demonstrated statistically significant superiority compared to ResNet, SENet, DenseNet, ShuffleNet, Transformer, and Swin Transformer architectures. P-values and confidence intervals were not reported for these comparisons.

Safety data regarding adverse events were not reported. Key limitations include the retrospective design and the need for prospective multicenter validation. The evidence holds promise as a valuable clinical decision-support tool, but external validation is required. Clinicians should interpret these findings cautiously given the study design. Funding or conflicts were not reported. Certainty is limited by external validation needs.

Imagine having a persistent cough that will not go away. You visit your doctor and feel worried.

They order a chest scan to look inside your lungs. The image shows something unusual.

But is it one dangerous infection or another?

Why Doctors Struggle With Lung Scans

Two lung diseases often look exactly the same on a picture. One is tuberculosis. The other is a rare bacteria.

They need different medicines to fight them. Taking the wrong one wastes time and hurts your health.

Doctors used to wait weeks for lab results to be sure.

The Surprising Shift in Diagnosis

Doctors used to rely on experience and guesswork. Sometimes they had to wait weeks for lab results.

Now, a new computer program looks at the images. It finds patterns humans might miss.

This technology changes how we approach complex cases.

How the Computer Sees the Difference

Think of the AI like a super-powered detective. It scans every pixel of the CT image.

It looks for tiny clues in the shadows and shapes of the lung tissue.

It learns from thousands of past cases to spot the truth.

What the Study Actually Tested

Researchers looked at scans from 409 patients. They split them into groups for training and testing.

The computer was pitted against six other AI models to see who was best.

They wanted to know which one was the smartest.

The Results Were Promising

The new model got it right about 84 percent of the time.

It beat all the other computer programs in the test group.

This doesn’t mean this treatment is available yet.

The score was high enough to show real potential.

What Experts Say About the Future

Doctors see this as a helper, not a replacement. It gives them more confidence.

It could speed up getting the right pills for patients who are sick.

It acts as a second pair of eyes for the medical team.

You cannot use this tool at home right now. It is still in the lab.

If you have lung issues, keep talking to your specialist about your care.

Do not try to diagnose yourself with online tools.

The Limits of This Research

The study looked at past records. It did not watch patients in real time.

The group was also relatively small for a global health issue.

More data is needed to be completely sure.

What Happens Next in Research

Scientists need to test this in more hospitals. They must prove it works everywhere.

Approval takes time. But this step brings us closer to faster answers for lung patients.

Future trials will check if it helps real people in real clinics.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Differentiating non-tuberculous mycobacterial lung disease (NTM-LD) from pulmonary tuberculosis (PTB) remains a significant clinical challenge owing to their overlapping clinical and imaging features, despite markedly different therapeutic strategies. A total of 409 patients with microbiologically confirmed diagnoses were retrospectively enrolled and randomly divided into a training set (n = 329; NTM-LD: 171, PTB: 158) and an independent test set (n = 80; NTM-LD: 41, PTB: 39). After lung segmentation with nnU-Net, images were intensity-normalized and resampled to 256 × 256 × 128 voxels. A 3D ResNeXt-based classifier was developed and compared against six mainstream deep learning architectures: ResNet, SENet, DenseNet, ShuffleNet, Transformer, and Swin Transformer. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and F1 score. The proposed 3D ResNeXt model achieved the highest performance, with an AUC of 0.89 and accuracy of 0.89 on the training set, and an AUC of 0.83 and accuracy of 0.84 on the independent test set. DeLong’s test confirmed statistically significant superiority over all six comparator architectures on the test set (all p  The 3D ResNeXt model demonstrated superior and interpretable performance in differentiating NTM-LD from PTB on chest CT. It holds promise as a valuable clinical decision-support tool, although prospective multicenter validation is warranted.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.